Experts Release Guidance on Liver-Related Toxicities With Gene Therapy for Hemophilia A | ASH Clinical News | American Society of Hematology
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Patients with hemophilia A who have received valoctocogene roxaparvovec gene therapy need to be managed carefully to minimize their risk of hepatotoxicity, according to new guidelines published in Blood Advances. The authors, an interdisciplinary group of 13 hepatology and hemophilia experts, suggest that a pretreatment assessment and ongoing monitoring of liver health after gene therapy administration may prevent
